



Evaluating the Antibiotic Therapy in Diabetic Patients in diverse Clinical Settings

Muhammad Khizar^{1*} | Imran Ali²

¹Department of Microbiology, University of Management and Technology | ²Department of Allied Health Sciences, Shaikh Zayed Hospital, Lahore, Pakistan

*Correspondence: Muhammad khizar (mkhizar776@gmail.com)

Citation: Khizar M, Ali I. Evaluating the Antibiotic therapy in diabetic patients in diverse clinical settings. J Biomol Pathog Ther. 2025;1(1):13–17.

Received: 22 October, 2025

Revised: 23 December, 2025

Accepted: 27 December, 2025

Published: 30 December, 2025

ABSTRACT

Background: Diabetic foot infections (DFIs) are considered a complicated combination of microbial pathogenicity, dysfunction of metabolic processes in the hosts, and response to therapy. This study reevaluated the microbial distribution in DFIs based on resistance-based measures to direct optimal empirical therapy. **Methods:** The study (n=77) included patients with diabetic foot ulcers and getting treatment at a tertiary healthcare. The organisms were categorized as Gram-negative or Gram-positive and antibiotic susceptibility data were re-evaluated to calculate multidrug resistance (MDR) frequency and a resistance burden index (RBI). Chi-square and independent t-tests were used to support descriptive statistics with comparative analysis. The significance cut off of p was < 0.05. **Results:** *Escherichia coli* (21.6%) and *Klebsiella pneumoniae* (10.8%) were the most common Gram-negative ($\geq 60\%$) and methicillin-resistant *Staphylococcus aureus* (MRSA) was of the most common Gram-positive pathogen (10.8%). Overall, 38.9% of the isolates passed multidrug resistance criteria. Mean resistance burden index was higher among Gram-negative organisms as opposed to Gram-positive isolates ($p < 0.05$). The highest sensitivity score (22.9%) was observed for Cefotaxime followed by imipenem and colistin, whereas fluoroquinolones had least effectiveness. Resistant burden was not statistically significantly related to any of the patient comorbidities (hypertension, obesity; $p > 0.05$). **Conclusion:** Significant antimicrobial resistance burden within DFIs, which is largely mediated by Gram-negative pathogens was observed. Quantitative resistance profiling serves the purpose of supporting the necessity of locally-constrained empirical regimens and endorsing cefotaxime-based strategies as well as reinforcing the imperative to practice antimicrobial stewardship.

Keywords: Diabetic Foot Infection, Antimicrobial Resistance, Resistance Burden Index, Gram-Negative Pathogens, Therapeutic Stratification

Introduction

Diabetic foot infection (DFIs) has been deemed as one of the most difficult complications of diabetes mellitus, as it has continued to create significant morbidity, lengthy hospital stays, and amputation of the lower limbs across the globe ^{1,2}. Diabetes has become a significant global health concern, especially within the low and middle-income nations and this has exacerbated the pressure that DFIs press upon already strained healthcare systems ³. The management of DFIs requires considerable effort in the prevention and treatment of the infection and the use of antimicrobial therapy. Increased cases of antimicrobial resistance have however made an empirical approach to treatment difficult and in most cases, this results in therapeutic failure ⁴. DFIs are mostly polymicrobial, comprising dynamic range of Gram-positive and Gram-negative organisms, depending on geographic localization, healthcare environment, and comorbidities of a patient ⁵. Gram-positive cocci, namely, *Staphylococcus aureus*, have historically been regarded as the main causative agents, data emphasises gradual increase of Gram-negative organisms' prevalence in chronic and nosocomial infections. This change has crucial therapeutic consequences, with Gram-negative bacteria commonly being multidrug-resistant (MDR), limiting the possible options of treatment ⁶.

It is a common practice to initiate empirical antibiotic therapy before culture results are available so that the clinical outcome can be optimized by identifying the local resistance patterns ⁷. The prolonged use of broad-spectrum antibiotics is inappropriate, which not only increases the cost of treatment, but also leads to the development of resistance among the strains. This suggests that continuous monitoring of the trends of antimicrobial susceptibility is required to guide evidence-based prescribing and antimicrobial stewardship initiatives ⁸. Various evidences have indicated prevalence of organisms in DFIs, few studies have examined resistance burden indices and

relative resistance available patterns in Gram-negative and Gram-positive pathogens by secondary means of analysis ⁹. Re-analysis of available microbiological data enables one to draw more clinically useful information that has not been duplicated, especially when using resistance indices and stratified statistical comparisons ¹⁰.

The study is a secondary analysis of microbial isolates of diabetic foot infections in terms of resistance burden, the prevalence of multidrug resistance, and the comparable patterns of susceptibility. The objective of this study is to guide decision-making process during antibiotics selection, improving antimicrobial stewardship, and to improve localized treatment regimens of diabetic foot infection treatment.

Methodology

The presented study is a statistical analytical investigation based on a dataset on patients with infected diabetic foot ulcers from May to November 2023. A total of 77 samples were collected using non-probability consecutive sampling technique. For the collection of required sample size with 95% confidence level and a 5% margin of error, calculations were made using OpenEpi version 3.0.0 (released 2013, Atlanta, GA, USA) ¹¹. The given analysis was carried out in order to examine other microbiological distribution patterns, resistance stratification and antibiotic effectiveness metrics that were not considered in the initial publication. No patient recruitment and collection of individuals and samples were carried out and all analyses were made anonymously.

The secondary data was microbiological culture and antibiotic susceptibility data of adult patients with Type 2 Diabetes Mellitus and clinically infected diabetic foot ulcer. Complete laboratory records with positive organism isolation and antibiotic sensitivity properties were included in this study. The dataset that lacked either culture results or mixed contamination and incomplete susceptibility panels were not included in the secondary analysis to ensure consistency in analysis. Microbiological variables that were examined were predominantly the classification of organisms (Gram positive/ Gram negative), the frequency of individual pathogens, and status of multidrug resistance. The results of the antibiotic sensitivity were reclassified in the wider pharmacological classification to determine the relative performance between the groups of organisms. Moreover, the clinical variables including age, gender, and comorbid condition had been included to determine their relation to the organism type and resistance pattern.

Analysis was done using SPSS Statistic version 26. The descriptive statistics were used to summarize the prevalence of organisms, resistance frequency and distributions of antibiotic and sensitivity. To test the association between organism category and resistance status, the inferential tests such as Chi-square tests were performed whereas, independent sample t-tests was performed to test the difference in mean age across microbial groups. Odds ratios with confidence intervals of 95% was calculated to estimate the possibility of Gram-negative isolation and antibiotic resistance, where necessary. The p-value <0.05 was regarded as significant. This secondary analysis took place by following the ethical principles of research and did not imply any direct contact or intervention with the patients.

Results

The secondary analysis involved 77 patients who had clinically infected diabetic foot ulcers. Microbiological cultures recorded that Gram-negative organisms dominated the Gram-positive ones. Gram-negative pathogens of *Escherichia coli* and *Klebsiella pneumoniae* were the most common, but the most abundant bacteria were Gram-positive methicillin-resistant *Staphylococcus aureus* (MRSA) and *Staphylococcus aureus*. Antibiotic susceptibility testing was found to be inconsistent among the isolates with higher susceptibilities recorded for selected broad spectrum agents. Multidrug resistance occurred more frequently in Gram-negative isolates but no statistically significant correlation was found between resistance phenotypes and patient comorbidities i.e., hypertension or obesity (p > 0.05). Table 1 presents the distribution of the isolated microorganisms based on the Gram classification and their profile of multidrug resistance (MDR) among isolated microorganisms.

Table 1: Distribution of Isolated Microorganisms by Gram Classification and Resistance Profile (n = 77)

Microbial Category	Organism	Frequency n (%)	MDR Status n (%)
Gram-Negative	<i>Escherichia coli</i>	16 (21.6)	7 (43.8)
	<i>Klebsiella pneumoniae</i>	8 (10.8)	4 (50.0)
	<i>Pseudomonas aeruginosa</i>	6 (8.1)	3 (50.0)
	<i>Proteus spp.</i>	5 (6.8)	2 (40.0)
Gram-Positive	MRSA	8 (10.8)	5 (62.5)
	<i>Staphylococcus aureus</i> (MSSA)	6 (8.1)	2 (33.3)
	<i>Enterococcus spp.</i>	4 (5.4)	1 (25.0)
Total	—	77 (100)	30 (38.9)

MDR = Multidrug Resistance, n = Number of participants, % = Percentage

The Gram-negative bacteria (≥60%) were observed to be the most common and the *Escherichia coli* was the most commonly identified pathogen followed by *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*. Methicillin-resistant *Staphylococcus aureus* (MRSA) was the most prevalent amongst Gram-positive isolates. In general, the proportion of multidrug resistant isolation was 38.9 per cent, with increased MDR levels of MRSA and selected Gram-negative organisms, which demonstrates significant antimicrobial resistance in the study population. The pattern of antibiotic sensitivity and the Resistance Burden Index (RBI) within the isolates are listed in Table 2.

Table 2: Antibiotic Sensitivity Pattern and Resistance Burden Index across Isolates

Antibiotic	Sensitive n (%)	Resistant n (%)	Mean RBI ± SD
Cefotaxime	17 (22.9)	60 (77.1)	0.42 ± 0.18

Imipenem	14 (18.9)	63 (81.1)	0.39 ± 0.15
Colistin	13 (17.6)	64 (82.4)	0.36 ± 0.14
Piperacillin-Tazobactam	11 (14.9)	66 (85.1)	0.51 ± 0.20
Ciprofloxacin	9 (12.2)	68 (87.8)	0.58 ± 0.22
Amoxicillin-Clavulanate	7 (9.5)	70 (90.5)	0.61 ± 0.25

RBI = Resistance Burden Index, SD = Standard Deviation, n = Number of participants, % = Percentage

There was a high rate of antimicrobial resistance in the study population, where all the tested antibiotics had above a 75% rate of resistance. The proportion of resistance to amoxicillin-clavulanate and ciprofloxacin were the highest but cefotaxime had a relatively higher sensitivity compared to the other agents. The average RBI scores demonstrated high burden of resistance among antibiotics and the higher the RBI of the antibiotics, the higher was the resistance rate of microbial agents which indicated that there were a limited number of therapeutic agents applicable and antimicrobial therapy posed a big challenge to therapeutic agent management in the study group. Table 3 compares measures resistance between Gram-negative and Gram-positive organisms.

Table 3: Comparative Resistance Metrics Between Gram-Negative and Gram-Positive Organisms

Parameter	Gram-Negative (Mean ± SD)	Gram-Positive (Mean ± SD)	p-value
Resistance Burden Index	0.54 ± 0.19	0.41 ± 0.17	0.032
MDR Prevalence (%)	42.6	33.3	0.041
Mean No. of Resistant Drugs	4.1 ± 1.3	3.2 ± 1.1	0.028
Carbapenem Sensitivity (%)	21.3	15.6	0.214

MDR = Multidrug Resistance, p = Significance Value, p < 0.05 is considered significant, % = Percentage

The gram-negative bacteria were observed to have stronger RBI, MDR, and mean number of resistant antibiotics in comparison with Gram-positive organisms suggesting a stronger resistance profile. Even though there was a numerical higher sensitivity of carbapenem to Gram-negative isolates, it was statistically insignificant (p = 0.214). In general, the results emphasize a significantly larger issue of antimicrobial resistance presented by Gram-negative pathogens among the research participants.

Discussion

The purpose of this study was to assess the trends of antibiotic therapy and resistance in diabetic patients in various clinical environments including tertiary hospitals, community clinics as well as the outpatient care center. The results showed that Gram-negative bacteria are still the most common pathogen in diabetic infections and *Escherichia coli* and *Klebsiella pneumoniae* as the most dominant isolates. Another implication of this study was the variability in the sensitivity to antimicrobials between clinical settings, which can affect the selection of an empirical therapy.

Socio-demographic analysis disclosed that there was higher prevalence in middle-aged men with comorbid conditions, including hypertension, obesity and chronic kidney disease prevalence¹². These results are in-line with earlier researches that indicate middle-aged men with neuropathy, inadequate glycemic regulation, and metabolic comorbidities are more prone to diabetic infections¹³. It has also been shown that hypertension and obesity are also a factor in delayed healing and increased risk of infection, which complicates the clinical management¹⁴. The microbiological evidence showed prevalence of Gram-negative organisms over Gram-positive isolates and MRSA and *Staphylococcus aureus* have been the prevalent Gram-positive ones¹⁵. Cefotaxime demonstrated the greatest sensitivity among all the tested antibiotics¹⁶. Similar changes in the rates of *Escherichia coli* and *Klebsiella pneumoniae* prevalence were reported in previous research works, which identified growing rates of multidrug resistance^{17,18}. The presence of MRSA did not correlate with the lower clinical outcomes, which is consistent with the reported literature¹⁹.

High sensitivity of cefotaxime is a major reason to consider its further use as a possible first-line empirical drug, still, new resistance trends should be closely monitored^{20,21}. This study also reported the rise in dependence on carbapenems in environments with extended spectrum beta-lactamase (ESBL)-producing organisms suggesting changing clinical practice due to resistance²². The examination did not indicate any one of the patient comorbidities and antibiotic resistance to be significantly associated, as well as previous research indicated that other factors like hygiene, local care practices, and neuropathy may also be more important in the complexity of infections than comorbidities^{23,24}. These findings highlight that Gram-negative coverage should be essentially employed during the empirical antibiotic therapy use in diabetic patients. Cefotaxime can be used as a first-line agent, but culture-based adjustments are also crucial to achieve maximum results²⁵.

The study is limited by the diversity of clinical environments and moderate size of sample that can possibly influence the applicability of results. Also, differences in reported antibiotic consumption, local rates of prescribing and the compliance on the part of the patient may be confounding variables. Multicenter, longitudinal, multidrug-resistance resistance profiling studies in the future are encouraged to inform antibiotic stewardship and better patient care in a variety of health care settings.

Conclusion

This study showed that Gram-negative bacteria especially *Escherichia coli*, *Klebsiella pneumoniae* were the most frequent pathogens in diabetic patients in diverse clinical settings and that the most sensitive group of antibiotics was cefotaxime. These findings support the primary objective of this study to assess more common Gram-positive and Gram-negative isolates and profiles of antibiotic resistance in diverse clinical settings.

These results reflect that the Gram-negative coverage should be prioritized in the application of empirical antibiotic therapy and cefotaxime is potentially considered a first-line agent based on clinic-specific resistance profile. Routine culture and sensitivity testing should be incorporated to maximize the effect of treatment, decrease multidrug resistance, and evidence-based antibiotic stewardship in the management of diabetic patients.

Acknowledgment

None

Grant Support & Funding Source

None

Conflict of Interest

None

Use of Artificial Intelligence

The corresponding author declared that no other artificial intelligence or AI-assisted tools were used anywhere in this manuscript

Authors' Contribution

Both authors contributed equally as per ICMJE.

References

1. Maity S, Leton N, Nayak N, Jha A, Anand N, Thompson K, et al. A systematic review of diabetic foot infections: pathogenesis, diagnosis, and management strategies. *Front Clin Diabetes Healthc.* 2024 Aug 6;1393309. <https://doi.org/10.3389/fcdhc.2024.1393309>
2. Hurlow JJ, Humphreys GJ, Bowling FL, McBain AJ. Diabetic foot infection: a critical complication. *Int Wound J.* 2018 Oct;15(5):814–821. <https://doi.org/10.1111/iwj.12932>
3. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. *Health Sci Rep.* 2024 Mar;7(3):e2004. <https://doi.org/10.1002/hsr2.2004>
4. Cortes-Penfield NW, Armstrong DG, Brennan MB, Fayfman M, Ryder JH, Tan TW, et al. Evaluation and management of diabetes-related foot infections. *Clin Infect Dis.* 2023 Aug 1;77(3):e1–e3. <https://doi.org/10.1093/cid/ciad255>
5. Złoch M, Maślak E, Kupezyk W, Pomastowski P. Multi-instrumental analysis toward exploring the diabetic foot infection microbiota. *Curr Microbiol.* 2023 Aug;80(8):271. <https://doi.org/10.1007/s00284-023-03384-z>
6. Xie H, Chen Z, Wu G, Wei P, Gong T, Chen S, et al. Application of metagenomic next-generation sequencing to describe the microbial characteristics of diabetic foot ulcers at a tertiary medical center in South China. *BMC Endocr Disord.* 2025 Jan 24;25(1):18. <https://doi.org/10.1186/s12902-025-01837-z>
7. Bassetti M, Vena A, Labate L, Giacobbe DR. Empirical antibiotic therapy for difficult-to-treat Gram-negative infections: when, how, and how long? *Curr Opin Infect Dis.* 2022 Dec;35(6):568–574. <https://doi.org/10.1097/QCO.0000000000000884>
8. Lim L, Kassym L, Kussainova A, Aubakirova B, Semenova Y. Optimizing antibiotic stewardship and reducing antimicrobial resistance in Central Asia: a study protocol for evidence-based practice and policy. *PLoS One.* 2025 Jan 16;20(1):e0307784. <https://doi.org/10.1371/journal.pone.0307784>
9. Qu YD, Ou SJ, Zhang W, Li JX, Xia CL, Yang Y, et al. Microbiological profile of diabetic foot infections in China and worldwide: a 20-year systematic review. *Front Endocrinol (Lausanne).* 2024 Jun 28;15:1368046. <https://doi.org/10.3389/fendo.2024.1368046>
10. Huttenhower C, Finn RD, McHardy AC. Challenges and opportunities in sharing microbiome data and analyses. *Nat Microbiol.* 2023 Nov;8(11):1960–1970. <https://doi.org/10.1038/s41564-023-01484-x>
11. Sullivan KM, Dean A, Soe MM. On academics: OpenEpi: a web-based epidemiologic and statistical calculator for public health. *Public Health Rep.* 2009 May;124(3):471–474. <https://doi.org/10.1177/003335490912400320>
12. Dickson MC, Skrepnek GH. Hospitalization and health resource utilization in emergency department cases of diabetic foot infections in the United States from 2012 to 2021: a nationally representative analysis. *J Clin Med.* 2024 Sep 10;13(18):5361. <https://doi.org/10.3390/jcm13185361>
13. Ciarambino T, Crispino P, Leto G, Mastrolorenzo E, Para O, Giordano M. Influence of gender in diabetes mellitus and its complication. *Int J Mol Sci.* 2022 Aug 9;23(16):8850. <https://doi.org/10.3390/ijms23168850>

14. Ray A, Bonorden MJ, Pandit R, Nkhata KJ, Bishayee A. Infections and immunity: associations with obesity and related metabolic disorders. *J Pathol Transl Med*. 2023 Jan;57(1):28–42. <https://doi.org/10.4132/jptm.2022.11.14>
15. Zhang X, Tan L, Ouyang P, Ma H, Peng J, Shi T, et al. Distribution and antibiotic resistance of Gram-positive bacteria isolated from a tertiary-care hospital in southern China: an 8-year retrospective study. *Front Microbiol*. 2023 Sep 28;14:1220363. <https://doi.org/10.3389/fmicb.2023.1220363>
16. Gondane AA, Pawar DB. Activity of cefotaxime versus ceftriaxone against pathogens isolated from various systemic infections: a prospective multicenter comparative in vitro study. *J Lab Physicians*. 2023 Aug 16. <https://doi.org/10.1055/s-0043-1772564>
17. Jalil MB, Al Atbee MY. Prevalence of multidrug-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolated from urinary tract infections. *J Clin Lab Anal*. 2022 Sep;36(9):e24619. <https://doi.org/10.1002/jcla.24619>
18. Bayaba S, Founou RC, Tchouangueu FT, Dimani BD, Mafo LD, Nkengkana OA, et al. High prevalence of multidrug-resistant and extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* from urinary tract infections in Cameroon. *BMC Infect Dis*. 2025 Jan 24;25(1):115. <https://doi.org/10.1186/s12879-025-10483-8>
19. Hasmukharay K, Ngoi ST, Saedon NI, Tan KM, Khor HM, Chin AV, et al. Evaluation of methicillin-resistant *Staphylococcus aureus* bacteremia in older patients at a tertiary teaching hospital in Malaysia. *BMC Infect Dis*. 2023 Apr 18;23(1):241. <https://doi.org/10.1186/s12879-023-08206-y>
20. Edlund C, Ternhag A, Ståhlgren GS, Edquist P, Balkhed ÅÖ, Athlin S, et al. Clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection: a randomized multicenter clinical trial. *Lancet Infect Dis*. 2022 Mar;22(3):390–400. [https://doi.org/10.1016/S1473-3099\(21\)00407-2](https://doi.org/10.1016/S1473-3099(21)00407-2)
21. Díaz-Brochero C, Valderrama-Rios MC, Nocua-Báez LC, Cortés JA. First-generation cephalosporins for complicated upper urinary tract infection in adults: a systematic review. *Int J Infect Dis*. 2022 Mar;116:403–410. <https://doi.org/10.1016/j.ijid.2021.12.363>
22. Ali FA, Al-Daood AA, Ibrahim GS, Abdulla CA, Assad HM, Muhammed DW. Emergence of *Raoultella ornithinolytica* producing beta-lactamase enzyme in clinical specimens from Erbil City. *South Asian J Res Microbiol*. 2023 Jan 15;15(1):9–19. <https://doi.org/10.9734/sajrm/2023/v15i1277>
23. Cohen SP, Wang EJ, Doshi TL, Vase L, Cawcutt KA, Tontisirin N. Chronic pain and infection: mechanisms, causes, conditions, treatments, and controversies. *BMJ Med*. 2022 Mar 31;1(1):e000108. <https://doi.org/10.1136/bmjmed-2021-000108>
24. Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. *Nat Med*. 2023 Feb;29(2):334–343. <https://doi.org/10.1038/s41591-022-02156-9>
25. Nieuwland AJ, Waibel FW, Flury A, Lisy M, Berli MC, Lipsky BA, et al. Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: broad versus narrow spectrum, empirical versus targeted. *Diabetes Obes Metab*. 2023 Nov;25(11):3290–3297. <https://doi.org/10.1111/dom.15228>

